Business Context and Reporting Period
Cytosorbents Corp (CTS) filed a Form 8-K on July 21, 2020, reporting a significant contract award. The Company is a Delaware corporation listed on the Nasdaq Capital Market.
Key Financial Metrics
This filing does not provide standard financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial figure disclosed is the value of a specific government award.
Material Changes
The Company received a U.S. Army Medical Research Acquisition Activity (USAMRAAA) Award for its HemoDefend platform. The award is for up to $4,421,487.00 to develop a highly efficient adsorber designed to remove anti-A and Anti-B antibodies from blood and plasma for transfusion. This award is supported by the U.S. Department of Defense Peer Reviewed Medical Research Program (PRMRP)/Congressionally Directed Medical Research Program (CDMRP) under Contract No. W81XWH2010712.
Outlook, Risks, and Contingencies
Management highlights the HemoDefend platform as a development-stage technology intended to safeguard blood supply quality and safety. A material risk noted is that HemoDefend is not yet approved in the U.S. or elsewhere. The award is contingent upon the successful development of the technology.
Investor Verification Checklist
- Verify the specific milestones and payment terms associated with Contract No. W81XWH2010712.
- Confirm the current regulatory status and development timeline for the HemoDefend platform.
- Review the Company's cash position to assess its ability to fund the development work alongside this award.
- Monitor future filings for updates on the approval status of HemoDefend.